SCM
TELO icon

Sterling Capital Management’s Telomir Pharmaceuticals TELO Stock Holding History

Sterling Capital Management’s Portfolio TELO Stock Details TELO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-148
Closed -$478 – 3422
2025
Q1 		$478 Sell
148
-121
-45% -$529 ﹤0.01% 2962
2024
Q4 		$1.11K Buy
269
+259
+2,590% +$1.22K ﹤0.01% 2920
2024
Q3 		$64 Buy
+10
New +$49 ﹤0.01% 3226

Other funds holding TELO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
SEM
Suncoast Equity Management Tampa, Florida $833M AUM 11.9% 1-Year Est. Return

Sterling Capital Management's TELO Position: Q2 2025 in Review

Sterling Capital Management sold out of Telomir Pharmaceuticals (TELO) in Q2 2025, closing a stake of 148 shares — an estimated $478 sold.

Sterling Capital Management first reported a position in TELO in Q3 2024 and held it in 3 quarters. The position peaked at $1.11K in Q4 2024. 43 funds tracked by Wall St. Rank hold TELO as of Q2 2025.

  • Sterling Capital Management reported no remaining Telomir Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Sterling Capital Management sold 148 Telomir Pharmaceuticals shares in Q2 2025, an estimated $478.
  • Sterling Capital Management first reported a position in Telomir Pharmaceuticals in Q3 2024 and held it in 3 quarters.
  • Sterling Capital Management's Telomir Pharmaceuticals position peaked at $1.11K in Q4 2024.
  • 43 funds tracked by Wall St. Rank held Telomir Pharmaceuticals as of Q2 2025.

Based on Sterling Capital Management's 13F filing for Q2 2025, filed 6 Aug 2025.